Table 2.
Some selected and most recent clinical trials (since January 1st 2016) on NK cell-based immunotherapies, in different forms of solid tumors, by using adoptive transfer of NK and CAR-NK cells.
| ADOPTIVE TRANSFER OF EX VIVO EXPANDED AND ACTIVATED NK CELLS | ||||
|---|---|---|---|---|
| NK cell source | In combination with | Phase | ClinicalTrial.gov identifier | Tumor |
| NK-92 | ALT-803 | II | NCT02465957 | MCC |
| Autologous vs. allogenic | – | II | NCT02853903 | Neoplasms |
| Autologous | – | E I | NCT03662477 | LC |
| – | II | NCT03410368 | NSCLC | |
| Bortezomib | I | NCT00720785 | PC, CoC, NSCLC | |
| Anti cancer drugs | II | NCT02734524 | NSCLC | |
| Anti-GD2 (Ch14.18) + lenalidomide | I | NCT02573896 | NB | |
| Sintilimab | II | NCT03958097 | NSCLC | |
| Allogenic | – | I | NCT03358849 | BTC |
| ALT-803 | I | NCT02890758 | CoC, AR, STS, ES, RS | |
| Anti-GD2 (Hu14.18)-IL2 fusion protein | I | NCT03209869 | NB | |
| Anti-GD2 + IL2 | I/II | NCT03242603 | NB | |
| Anti-GD2 (Hu3F8) + rIL2 | I | NCT02650648 | NB | |
| Pemetrexed | I | NCT03366064 | NSCLC | |
| NK cells (not specified) | – | I | NCT03619954 | AST, OC |
| Trastuzumab | I/II | NCT02843126 | BC | |
| Cetuximab | I/II | NCT02845856 | NSCLC | |
| Anti-VEGF (bevacizumab) | I/II | NCT02857920 | Neoplasms | |
| Nivolumab | I/II | NCT02843204 | Neoplasms | |
| Irreversible electroporation (IRE) | I/II | NCT02718859 | PC | |
| I/II | NCT03008343 | LiC | ||
| Cryosurgery | I/II | NCT02843802 | LiC | |
| I/II | NCT02844335 | BC | ||
| I/II | NCT02849379 | ToC | ||
| I/II | NCT02849314 | LaC | ||
| I/II | NCT02849327 | PhC | ||
| I/II | NCT02849340 | CeC | ||
| I/II | NCT02849015 | LiC | ||
| I/II | NCT02843581 | MEC | ||
| I/II | NCT02849353 | OC | ||
| I/II | NCT02843815 | NSCLC | ||
| I/II | NCT02843607 | RCC | ||
| I/II | NCT02849366 | RS | ||
| NKT cells | I | NCT03198923 | NSCLC | |
| CIK | DCs | I/II | NCT03047525 | CcC, RC, NC, LC |
| UCB-derived | – | I/II | NCT03634501 | LC, BC, CoC, PC, OC |
| Anti cancer drugs | I | NCT03420963 | AST | |
| I | NCT03539406 | OC | ||
| iPSC-derived (FATE-NK100) | IL-2 | I | NCT03213964 | OC |
| Anti-HER2/neu and anti-EGFR | I | NCT03319459 | BC, CoC, HNSCC, HC, NSCLC, RCC, PC, M | |
| iPSC-derived (FT500) | – | n. i. | NCT04106167 | Neoplasms |
| Immune checkpoint inhibitors | I | NCT03841110 | Neoplasms | |
| ADOPTIVE TRANSFER OF CAR-NK CELLS | ||||
| CAR NK cells | In combination with | Phase state | ClinicalTrial.gov identifier | Tumor |
| CD16A-IL2-NK-92 (haNK) | – | I | NCT03027128 | LAST |
| IL-15 superagonist (N-803) and avelumab | II | NCT03853317 | MCC | |
| Anti-cancer drugs, vaccines and immune checkpoint inhibitors | I/II | NCT03387111 | SCC, neoplasms | |
| ROBO1-NK cells | – | I/II | NCT03940820 | Neoplasms |
| BiCAR-NK cells (ROBO1 CAR-NK cells) | – | I/II | NCT03941457 | PC |
| ErbB2/HER2-NK (NK-92/5.28z) | Intracranial application | I | NCT03383978 | GB |
| NKG2D-NK | IL-2 | I | NCT03415100 | Neoplasms, OC |
| MUC1-NK | – | I/II | NCT02839954 | HC, NSCLC, PC, TNIBC, MGB, CoC, GC |
Abbreviation of solid tumors and immune checkpoint inhibitors reported in the column indicating the “combination” treatment: see Table 1 legend.
Abbreviation of cells: DCs, dendritic cells; CIK, Cytokine-induced killer cells; NKT, natural killer-T cells; iPSC, induced pluripotent stem cells; UCB, umbilical cord blood. Other abbreviations: E I, early I phase; n. i., non-interventional, observational study.